Russell Investments Group Ltd. lowered its position in Gilead Sciences, Inc. (NASDAQ:GILD) by 6.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,047,191 shares of the biopharmaceutical company’s stock after selling 67,933 shares during the period. Russell Investments Group Ltd. owned about 0.08% of Gilead Sciences worth $74,147,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Hall Laurie J Trustee raised its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock worth $100,000 after buying an additional 250 shares during the period. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock worth $110,000 after buying an additional 1,400 shares during the period. Dubuque Bank & Trust Co. raised its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 267 shares during the period. Penserra Capital Management LLC raised its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock worth $112,000 after buying an additional 144 shares during the period. Finally, Webster Bank N. A. raised its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock worth $125,000 after buying an additional 624 shares during the period. Institutional investors own 74.04% of the company’s stock.

Gilead Sciences, Inc. (NASDAQ:GILD) traded up 2.30% during trading on Monday, reaching $75.49. The company had a trading volume of 12,278,235 shares. Gilead Sciences, Inc. has a 12-month low of $63.76 and a 12-month high of $82.07. The firm has a market capitalization of $98.58 billion, a PE ratio of 8.20 and a beta of 1.21. The firm’s 50 day moving average price is $72.97 and its 200 day moving average price is $68.86.

Gilead Sciences (NASDAQ:GILD) last announced its quarterly earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.11 by $0.45. Gilead Sciences had a return on equity of 66.07% and a net margin of 42.90%. The company had revenue of $7.14 billion for the quarter, compared to the consensus estimate of $6.35 billion. During the same quarter in the previous year, the business earned $3.08 EPS. Gilead Sciences’s revenue was down 8.2% compared to the same quarter last year. Analysts anticipate that Gilead Sciences, Inc. will post $8.74 earnings per share for the current year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 28th. Shareholders of record on Friday, September 15th will be given a dividend of $0.52 per share. The ex-dividend date is Thursday, September 14th. This represents a $2.08 annualized dividend and a yield of 2.82%. Gilead Sciences’s payout ratio is 22.58%.

ILLEGAL ACTIVITY WARNING: This article was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this article on another site, it was illegally stolen and republished in violation of US and international copyright laws. The legal version of this article can be viewed at https://www.thecerbatgem.com/2017/08/28/gilead-sciences-inc-gild-shares-sold-by-russell-investments-group-ltd.html.

A number of brokerages have recently commented on GILD. BidaskClub lowered Gilead Sciences from a “buy” rating to a “hold” rating in a report on Wednesday, August 9th. Maxim Group reiterated a “hold” rating on shares of Gilead Sciences in a report on Monday. Vetr lowered Gilead Sciences from a “strong-buy” rating to a “buy” rating and set a $82.15 price target for the company. in a report on Monday. Deutsche Bank AG reiterated a “buy” rating and set a $81.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Thursday, July 27th. Finally, Berenberg Bank reiterated a “buy” rating and set a $86.00 price target (up from $79.00) on shares of Gilead Sciences in a report on Sunday, August 20th. Eleven equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $80.58.

In other Gilead Sciences news, insider John C. Martin sold 73,333 shares of Gilead Sciences stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the sale, the insider now directly owns 3,199,969 shares of the company’s stock, valued at approximately $227,197,799. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, EVP Gregg H. Alton sold 40,000 shares of Gilead Sciences stock in a transaction that occurred on Friday, July 21st. The shares were sold at an average price of $74.00, for a total value of $2,960,000.00. Following the sale, the executive vice president now directly owns 137,488 shares in the company, valued at $10,174,112. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 206,666 shares of company stock worth $15,223,184. Insiders own 1.30% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Institutional Ownership by Quarter for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.